If granted, Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) would be the first protein-based option for adolescents aged 12-17 years in EuropeGAITHERSBURG, Md., March 31, 2022 /PRNewswire/
First authorization of Novavax' COVID-19 vaccine in adolescent population receivedCovovax (SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine) is the first protein-based